Clinical laboratories still face uncertainty and the difficult decision of whether to start the work needed to comply with the with Phase 1 expectations under FDA’s Laboratory Developed Tests Final Rule (the “LDT Final Rule”), which remain set to go into effect on May 6, 2025. To be sure, the shift in priorities of the new administration has kept the health care industry on its toes for the last few weeks, especially as the leadership and messaging of the Department of Health and Human Services (“HHS”) has started to come into sharper focus. The theme of ‘deregulation’, particularly when it comes to the activities of the Food and Drug Administration (“FDA”), has sparked interest and discussion among stakeholders in the life sciences industry – including clinical laboratories that are weighing how to approach the upcoming May 6 deadline for compliance.
We discussed the details of the LDT Final Rule in a previous Insight, explaining that as of the May 6, 2025 Phase 1 deadline FDA will expect all laboratories that manufacture LDTs to comply with medical device reporting (“MDR”) requirements, correction and removal reporting requirements, and quality system (“QS”) requirements regarding complaint files.
Blog Editors
Recent Updates
- Brand Licensing in Health Care: An Overview for Hospitals
- FDA Proposal Would Extend Food Traceability Rule’s Compliance Deadline to July 2028
- NYDFS Cybersecurity Crackdown: New Requirements Now in Force, and "Covered Entities" Include HMOs, CCRCs—Are You Compliant?
- The Case for Regular Legal Maintenance: A Litigation Readiness Mindset for Modern Health Care Organizations
- The Rising Threats of Multi-Modal and Agentic AI in Cyber Attacks